28.84

2.14% -0.63

After Hours: 28.70 -0.14 -0.49%

Apellis Pharmaceuticals Inc (APLS)

Overview News Price History Option Chain Financials Why APLS Down? Discussions Forecast

Apellis Pharmaceuticals Inc stock is traded at $28.84, with a volume of 2.30M. It is down -2.14% in the last 24 hours and down -25.86% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Previous Close:

$29.47

Open:

$29.17

24h Volume:

2.30M

Relative Volume:

1.44

Market Cap:

$3.49B

Revenue:

$524.07M

Net Income/Loss:

$-417.27M

P/E Ratio:

-5.4933

EPS:

-5.25

Net Cash Flow:

$-550.91M

1W Performance:

-11.86%

1M Performance:

-25.86%

6M Performance:

-50.94%

1Y Performance:

-24.19%

1-Day Range:

$28.32

$29.36

1-Week Range:

$28.32

$32.78

52-Week Range:

$28.32

$73.80

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name

Apellis Pharmaceuticals Inc

Sector

Healthcare (1203)

Industry

Biotechnology (681)

Phone

617-977-5700

Address

100 FIFTH AVENUE, WALTHAM, KY

Employee

702

Twitter

@ApellisPharma

Next Earnings Date

2024-10-30

Latest SEC Filings

APLS's Discussions on Twitter

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-24	Upgrade	Jefferies	Hold → Buy
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-02-23	Initiated	Mizuho	Neutral
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Aug-29-23	Reiterated	Citigroup	Buy
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-10-22	Downgrade	Jefferies	Buy → Hold
Jul-19-22	Initiated	H.C. Wainwright	Buy
Jun-17-22	Resumed	Stifel	Buy
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Downgrade	ROTH Capital	Buy → Neutral
Sep-10-21	Reiterated	BMO Capital Markets	Outperform
Sep-10-21	Reiterated	Credit Suisse	Neutral
Sep-10-21	Reiterated	Needham	Buy
Sep-10-21	Reiterated	Oppenheimer	Outperform
Sep-10-21	Downgrade	Wedbush	Outperform → Neutral
Aug-19-21	Initiated	Jefferies	Buy
Aug-19-21	Upgrade	Wedbush	Neutral → Outperform
May-21-21	Initiated	UBS	Buy
Apr-16-21	Initiated	Goldman	Buy
Nov-19-20	Initiated	Needham	Buy
Sep-01-20	Initiated	Stifel	Buy
Jul-20-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Neutral
Apr-01-20	Initiated	Raymond James	Strong Buy
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-11-20	Upgrade	Wedbush	Underperform → Neutral
Jan-07-20	Initiated	SVB Leerink	Mkt Perform
Dec-19-19	Initiated	BofA/Merrill	Buy
Nov-22-19	Initiated	Wedbush	Underperform
Nov-05-19	Initiated	Credit Suisse	Neutral
Aug-01-19	Reiterated	Cantor Fitzgerald	Overweight
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-30-18	Upgrade	B. Riley FBR	Neutral → Buy
May-24-18	Initiated	Cantor Fitzgerald	Overweight
Apr-12-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-08-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

08:58 AM

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Significant Drop in Short Interest - MarketBeat

08:58 AM

05:40 AM

Algert Global LLC Raises Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

05:40 AM

Sep 28, 2024

How to Take Advantage of moves in (APLS) - Stock Traders Daily

Sep 28, 2024

Hsbc Holdings PLC Sells 63,626 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Sep 28, 2024

Sep 27, 2024

Apellis Pharma stock hits 52-week low at $29.57 By Investing.com - Investing.com Canada

Sep 27, 2024

Apellis Pharma stock hits 52-week low at $29.57 By Investing.com - Investing.com Australia

Sep 27, 2024

Apellis Pharma stock hits 52-week low at $29.57 - Investing.com

Sep 27, 2024

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues - Simply Wall St

Sep 27, 2024

Q2 2026 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Lowered by Zacks Research - MarketBeat

Sep 27, 2024

Ensign Peak Advisors Inc Decreases Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Sep 27, 2024

Sep 26, 2024

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU - MSN

Sep 26, 2024

Sep 25, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day - EIN News

Sep 25, 2024

Sep 24, 2024

Wells Fargo & Company Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $43.00 - MarketBeat

Sep 24, 2024

Sep 23, 2024

Mizuho cuts Apellis Pharmaceuticals target with Neutral rating By Investing.com - Investing.com Canada

Sep 23, 2024

Apellis Pharmaceuticals stock target cut on CHMP opinion By Investing.com - Investing.com Canada

Sep 23, 2024

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU - Yahoo Finance

Sep 23, 2024

Robert W. Baird Trims Apellis Pharmaceuticals (NASDAQ:APLS) Target Price to $92.00 - MarketBeat

Sep 23, 2024

Profund Advisors LLC Buys 20,435 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Sep 23, 2024

Sep 22, 2024

Apellis Pharmaceuticals declines afters CHMP's third negative opinion on Syfovre - MSN

Sep 22, 2024

Sep 21, 2024

Apellis Pharma stock hits 52-week low at $33.25 amid market challenges - Investing.com Canada

Sep 21, 2024

Sep 20, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 12-Month Low at $32.57 - MarketBeat

Sep 20, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat

Sep 20, 2024

Apellis Pharma stock hits 52-week low at $33.25 amid market challenges - Investing.com

Sep 20, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $39.00 at Mizuho - MarketBeat

Sep 20, 2024

Apellis Pharma stock hits 52-week low at $33.25 amid market challenges - Investing.com Australia

Sep 20, 2024

Geographic Atrophy (GA) Market Size to Hit USD 50.0 Billion by 2032 with a 8.6% CAGR – SNS Insider - GlobeNewswire Inc.

Sep 20, 2024

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Edgestream Partners L.P. - MarketBeat

Sep 20, 2024

Apellis: CHMP Once Again Recommends Against Syfovre - MarketWatch

Sep 20, 2024

Apellis eye drug again turned back in Europe - Yahoo Finance

Sep 20, 2024

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination - StockTitan

Sep 20, 2024

Sep 17, 2024

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells $1,340,510.00 in Stock - MarketBeat

Sep 17, 2024

Trend Tracker for (APLS) - Stock Traders Daily

Sep 17, 2024

Sep 16, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4.4% After Analyst Downgrade - MarketBeat

Sep 16, 2024

Sep 15, 2024

Arizona State Retirement System Buys 2,473 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World

Sep 15, 2024

Sep 14, 2024